Mayen-Herrera E, Cortina-de la Fuente D, Gómez-García C

Language: Spanish
References: 10
Page: 91-95
PDF size: 274.30 Kb.

ABSTRACT

Objective: To evaluate the economic impact of the use of levosimendan compared to dobutamine, in patients with Acute Heart Failure (AHF) in Mexico. Material and methods: A literature review and a budget impact analysis were developed to demonstrate economic advantages of levosimendan, compared to dobutamine, based on an economic model which considers length of stay in general ward and intensive care unit. The model evaluates the total cost of a hypothetical cohort of 1,000 patients by comparing the cost of treating AHF patients. Results: Medical costs per patient were MXN $108,673 when treated with levosimendan and MXN $117,782 for a patient receiving dobutamine. Total costs, show potential savings of MXN $9,100 per patient when using levosimendan. Results from the cohort suggested that levosimendan is a source of potential savings of around MXN $9,100,000. The estimated eligible population to receive inotropic treatment in Mexico is approximately 45,119. Assuming that the whole population is treated with levosimendan rather than dobutamine, this represents potential savings of MXN $410 million for the Mexican Public Health System. Conclusions: The use of levosimendan represents an important source of potential savings for the Mexican public Health System in patients with AHF.

REFERENCES

1. Arias M, et al. Insuficiencia cardiaca aguda e insuficiencia cardiaca descompensada. Arch Cardiol Méx 2007; 77(Supl 1): 27-33.

2. Cobo AC et al. Nesiritide. Tratamiento actual de la insuficiencia cardiaca aguda descompensada. Rev Mex Cardiol 2006; 17: 106-109.

3. Consejo Nacional de Población, http://www.conapo.gob.mx/index.php?option=com_content&view=article&id=36&Itemid=234. Mexico.

4. De Lissovoy G et al. Hospital costs for the treatment of acute heart failure: economic analysis of the REVIVE II study. Eur J Health Econ 2010;11:185-193.

5. Diario Oficial de la Federación, www.dof.gob.mx, (Publicado el 6 de marzo de 2009).

6. Follath F et al. Efficacy and safety of intrevenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized double-blind trial. Lancet 2002; 360: 196-202.

7. García-Peña C. El envejecimiento de la población asegurada por el IMSS: Implicaciones demográficas económicas y para los servicios de salud. Conferencia Regional Americana AISS-CISS. November the 3rd – 7th, 2003. www.imss.gob.mx/NR/rdonlyres/F1FD241DC810427BB5BFB6D952187CB8/0/DraMarIadelCarmenGarcIaPeNa.ppt+insuficiencia+cardiaca&cd=4&hl=es&ct=clnk&gl=us&client=google-coop-np. Consulted on April the 22nd, 2010.

8. Klabunde R. Cardiovascular Physiology Concepts, 2007, en http://www.cvphysiology.com/Heart%20Failure/HF002.htm, consulted on April the 10th 2010.

9. Reynales-Shigematsu LM et al. Costos de atención médica atribuibles al tabaquismo en el IMSS, Morelos. Sal Púb Méx 2005; 47: 451-457.

10. Romero AJ et al. Progresos en la insuficiencia cardiaca. Med Inten Méx 2007; 23: 321-329.